Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2016  |  Volume : 29  |  Issue : 2  |  Page : 319-323

CD19+CD5+ B-cell expansion and risk of pre-eclampsia


1 Department of Clinical Pathology, Faculty of Medicine, Menoufia University, Menoufia, Egypt
2 Department of Obstetrics and Gynecology, Faculty of Medicine, Menoufia University, Menoufia, Egypt

Correspondence Address:
Sara M Eldeeb
Department of Clinical Pathology, Faculty of Medicine, Menoufia University, 83 Saad Zaghlol St, El Bar El Sharky, Shebin El Kom, Menofia, 32511
Egypt
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/1110-2098.192433

Rights and Permissions

Background: Pre-eclampsia (PE) is a devastating pregnancy-associated disorder affecting 5–8% of pregnant women worldwide. It emerges as an autoimmune-driven disease. The autoantibodies against angiotensin type 1 receptor II have been proposed to account for PE symptoms. CD19(+)CD5(+) B-1a B cells constitute the main source of natural and polyreactive antibodies, which can be directed against own structures. Objectives: The aim of this study was to identify the B-cell subpopulation responsible for autoantibody production during PE and its correlation with b subunit of hCG levels. CD19+CD5+ B-cell percentages were measured using flow cytometry in 36 PE women in their third trimester (20 severe and 16 mild) and 15 age-matched normotensive pregnant women with normally developing pregnancies in their third trimester. Patients and methods: We observed significantly higher levels of frequency of CD19+/CD5+ B lymphocytes in the mild and severe PE groups compared with the levels observed in normotensive women with normally developing pregnancies in the third trimester (mild PE, 28.7 ± 14.3%, n = 16; severe PE, 29.9 ± 9.8%, n = 20; control, 11.3 ± 6.4%, n = 15; P < 0.01 and P < 0.001, respectively). However, comparison of the mild PE group with the severe PE group showed comparable levels of CD19+/CD5+ B cells (P > 0.05). Results: Correlation between the percentages of CD19+/CD5+ B lymphocytes and b hCG levels was not significant. Moreover, correlations between the percentages of CD19+/CD5+ B lymphocytes and other laboratory parameters were not significant. Conclusion: CD19+/CD5+ cells emerge as a novel PE marker. Their frequency does not seem to be regulated by the increased serum hCG levels. The detection and quantification of CD19+/CD5+ cells in maternal blood may open vast new therapeutic opportunities.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed534    
    Printed0    
    Emailed0    
    PDF Downloaded48    
    Comments [Add]    

Recommend this journal